The use of incretin-based therapies—particularly glucagon-like-peptide-1 receptor agonists (GLP-1RA) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists—has surged in recent years, revolutionizing the treatment of obesity and type 2 diabetes. These medications, originally developed to support blood glucose regulation, have demonstrated significant effects on appetite control, weight loss, and cardiometabolic health. As their use expands to […]
Posted On: 2025-10-31